Groove Botanicals (GRVE) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GRVE SEC filings page.
This page shows Groove Botanicals Inc (GRVE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported obligations are rising against a very small asset base, while short-term coverage remains nearly absent in FY2026.
From FY2025 to FY2026, total assets edged down to$4K while total liabilities increased to$1.47M ; that combination left the current ratio at just 0.0x, indicating liabilities vastly exceed readily available assets.
The latest filing reports negative equity of
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We do not publish a peer-relative financial health score for Groove Botanicals Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Groove Botanicals Inc earned $0.00 per diluted share (EPS) in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q1 2027.
Not reported for Q1 2027.
Not reported for Q1 2027.
Cash & Balance Sheet
Groove Botanicals Inc held $1K in cash as of Q1 2027; no long-term debt figure is on record for that period.
Not reported for Q1 2027.
Not reported for Q1 2027.
Margins & Returns
None of these metrics is reported for Q1 2027.
Capital Allocation
None of these metrics is reported for Q1 2027.
GRVE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | N/A | N/A | $16K-7.0% | $17K-9.9% | N/A | N/A | $17K | $18K |
| Operating Income | N/A | N/A | N/A | -$32Kn/m | N/A | N/A | N/A | -$30K |
| Net Income | N/A | N/A | N/A | -$32Kn/m | N/A | N/A | N/A | -$30K |
| EPS (Basic) | N/A | N/A | N/A | N/A | $0.00n/m | -$0.01n/m | $0.00n/m | $0.00n/m |
| EPS (Diluted) | $0.00n/m | -$0.01n/m | $0.00n/m | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00n/m | $0.00n/m |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | 60M0.0% | N/A | 60M+1.7% | 60M+1.7% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Interest Expense, Income Tax.
GRVE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3K-31.5% | $4K-1.9% | $6K+32.3% | $8K-26.6% | $4K+20.7% | $5K+111.0% | $5K+88.9% | $11K+245.2% |
| Current Assets | $3K-31.5% | $4K-1.9% | $6K+32.3% | $8K-26.6% | $4K+20.7% | $5K+111.0% | $5K+88.9% | $11K+245.2% |
| Cash & Equivalents | $1K-45.4% | $2K-26.4% | $1K+19.4% | $1K-75.7% | $3K+3.8% | $2K+21.0% | $1K-41.8% | $6K+115.5% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $1.5M+28.2% | $1.5M+32.2% | $1.4M+34.6% | $1.3M+37.0% | $1.2M+41.1% | $1.1M+46.1% | $1.0M+58.5% | $947K+50.7% |
| Current Liabilities | $1.5M+28.2% | $1.5M+32.2% | $1.4M+34.6% | $1.3M+37.0% | $1.2M+41.1% | $1.1M+46.1% | $1.0M+57.8% | $947K+47.5% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | -$1.5Mn/m | -$1.5Mn/m | -$1.4Mn/m | -$1.3Mn/m | -$1.2Mn/m | -$1.1Mn/m | -$1.0Mn/m | -$936Kn/m |
| Retained Earnings | -$35.6Mn/m | -$35.6Mn/m | -$35.5Mn/m | -$35.4Mn/m | -$35.3Mn/m | -$35.2Mn/m | -$35.1Mn/m | -$35.0Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GRVE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
GRVE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$1.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Groove Botanicals Inc GRVE | FY2026 | N/A | N/A | N/A | $361K | — |
| Strata PWR Corp SPOWF | FY2025 | $76K | -$39K | -50.6% | $187K | — |
Where Groove Botanicals Inc Ranks
Frequently Asked Questions
Groove Botanicals Inc (GRVE) had $4K in total assets as of fiscal year 2026, including both current and long-term assets.
Groove Botanicals Inc (GRVE) had a current ratio of 0.00 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
Groove Botanicals Inc (GRVE) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $361K as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Groove Botanicals Inc (GRVE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $361K as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Groove Botanicals Inc (GRVE) has negative shareholder equity of -$1.5M as of fiscal year 2026, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.